IL-17A moonlighting in lung type 2 immunity.

Mucosal Immunol

Centre for Molecular Therapeutics, The Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

Published: November 2020

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388737PMC
http://dx.doi.org/10.1038/s41385-020-0329-zDOI Listing

Publication Analysis

Top Keywords

il-17a moonlighting
4
moonlighting lung
4
lung type
4
type immunity
4
il-17a
1
lung
1
type
1
immunity
1

Similar Publications

Aminopeptidase N/CD13 Crosslinking Promotes the Activation and Membrane Expression of Integrin CD11b/CD18.

Biomolecules

October 2023

Instituto de Investigaciones Biomédicas, Departamento de Inmunología, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.

The β2 integrin CD11b/CD18, also known as complement receptor 3 (CR3), and the moonlighting protein aminopeptidase N (CD13), are two myeloid immune receptors with overlapping activities: adhesion, migration, phagocytosis of opsonized particles, and respiratory burst induction. Given their common functions, shared physical location, and the fact that some receptors can activate a selection of integrins, we hypothesized that CD13 could induce CR3 activation through an inside-out signaling mechanism and possibly have an influence on its membrane expression. We revealed that crosslinking CD13 on the surface of human macrophages not only activates CR3 but also influences its membrane expression.

View Article and Find Full Text PDF

IL-17A moonlighting in lung type 2 immunity.

Mucosal Immunol

November 2020

Centre for Molecular Therapeutics, The Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!